Skip to content

JBIO JBIO Short-Term Investments

Short-Term Investments at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.75B+14.9%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$130.59M
Vera Therapeutics logo
Vera TherapeuticsVERA
$482.41M-9.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$37.99M-84.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$57.01M
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$276.8M+21.8%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's short-term investments?
JBIO (JBIO) reported short-term investments of $256.21M in Q1 2026.
How has JBIO's short-term investments changed year-over-year?
JBIO's short-term investments increased by 700.9% year-over-year, from $31.99M to $256.21M.
What is the long-term trend for JBIO's short-term investments?
Over 4 years (2021 to 2025), JBIO's short-term investments has grown at a 21.6% compound annual growth rate (CAGR), from $113.18M to $247.72M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.